GB201322456D0 - Radiotracer compositions and methods - Google Patents

Radiotracer compositions and methods

Info

Publication number
GB201322456D0
GB201322456D0 GBGB1322456.3A GB201322456A GB201322456D0 GB 201322456 D0 GB201322456 D0 GB 201322456D0 GB 201322456 A GB201322456 A GB 201322456A GB 201322456 D0 GB201322456 D0 GB 201322456D0
Authority
GB
United Kingdom
Prior art keywords
methods
radiotracer
compositions
radiotracer compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1322456.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to GBGB1322456.3A priority Critical patent/GB201322456D0/en
Publication of GB201322456D0 publication Critical patent/GB201322456D0/en
Priority to CN201480069324.9A priority patent/CN105848687B/zh
Priority to JP2016539089A priority patent/JP6824738B2/ja
Priority to EP14814895.0A priority patent/EP3082879A1/en
Priority to US15/102,952 priority patent/US10300156B2/en
Priority to PCT/EP2014/078609 priority patent/WO2015091882A1/en
Priority to US16/375,223 priority patent/US11311636B2/en
Priority to JP2019124883A priority patent/JP2019206533A/ja
Priority to US17/695,810 priority patent/US20220202965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
GBGB1322456.3A 2013-12-18 2013-12-18 Radiotracer compositions and methods Ceased GB201322456D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1322456.3A GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods
CN201480069324.9A CN105848687B (zh) 2013-12-18 2014-12-18 放射性示踪剂组合物和方法
JP2016539089A JP6824738B2 (ja) 2013-12-18 2014-12-18 放射性トレーサー組成物及び方法
EP14814895.0A EP3082879A1 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
US15/102,952 US10300156B2 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
PCT/EP2014/078609 WO2015091882A1 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods
US16/375,223 US11311636B2 (en) 2013-12-18 2019-04-04 Radiotracer compositions and methods
JP2019124883A JP2019206533A (ja) 2013-12-18 2019-07-04 放射性トレーサー組成物及び方法
US17/695,810 US20220202965A1 (en) 2013-12-18 2022-03-15 Radiotracer compositions and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1322456.3A GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods

Publications (1)

Publication Number Publication Date
GB201322456D0 true GB201322456D0 (en) 2014-02-05

Family

ID=50071052

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1322456.3A Ceased GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods

Country Status (6)

Country Link
US (3) US10300156B2 (enExample)
EP (1) EP3082879A1 (enExample)
JP (2) JP6824738B2 (enExample)
CN (1) CN105848687B (enExample)
GB (1) GB201322456D0 (enExample)
WO (1) WO2015091882A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN108218651B (zh) * 2018-02-27 2023-11-03 首都医科大学宣武医院 用于制备放射性药物的一次性辅助装置及方法
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
GB201919016D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare Ltd Apparatus and method for solid phase extraction
MX2022008571A (es) * 2020-01-10 2022-11-30 Real Isolates Llc Metodos para la obtencion de compuestos a partir de un material vegetal o de hongos, composiciones respectivas y usos de los mismos.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
ES2347535T3 (es) * 2002-11-05 2010-11-02 Ion Beam Applications S.A. Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol.
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
JP5317475B2 (ja) 2005-10-24 2013-10-16 富士フイルムＲｉファーマ株式会社 肝細胞増殖因子受容体が関与する疾患の診断薬及び治療薬
CA2656487A1 (en) 2006-07-07 2008-01-17 The Board Of Trustees Of The Leland Stanford Junior University Selective caspase inhibitors
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
WO2011008990A1 (en) 2009-07-15 2011-01-20 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
BRPI0721424A2 (pt) 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
RU2475266C2 (ru) 2007-05-16 2013-02-20 ДжиИ Хелткер АС Оптические агенты визуализации
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
EP2268609B1 (en) * 2008-02-28 2013-01-30 GE Healthcare Limited Synthesis of a PEG-6 moiety from commercial low-cost chemicals
US8435454B2 (en) * 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
CA2819347A1 (en) 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
KR20130124522A (ko) * 2010-12-09 2013-11-14 지이 헬쓰케어 리미티드 방사성 추적자 조성물
MX2013007364A (es) * 2010-12-21 2014-03-21 Ge Healthcare Ltd Uso de anilina en la radioestabilizacion de ligadura de oxima.
SG191338A1 (en) 2010-12-22 2013-07-31 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods

Also Published As

Publication number Publication date
WO2015091882A1 (en) 2015-06-25
JP2019206533A (ja) 2019-12-05
US20220202965A1 (en) 2022-06-30
US20160303263A1 (en) 2016-10-20
US11311636B2 (en) 2022-04-26
CN105848687B (zh) 2020-06-09
JP6824738B2 (ja) 2021-02-03
US10300156B2 (en) 2019-05-28
CN105848687A (zh) 2016-08-10
US20190275182A1 (en) 2019-09-12
JP2017502946A (ja) 2017-01-26
EP3082879A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
GB2527241B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB201308072D0 (en) Compositions and methods
IL244850A0 (en) Stabilized epinaconazole preparations, and their uses
IL241225A0 (en) Plant-based compositions and their uses
IL265876A (en) Preparations that include 15-ohepa and methods of using them
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
GB201321693D0 (en) Composition and uses thereof
SG11201509448WA (en) Creamer compositions and uses thereof
GB201305414D0 (en) Method and composition
GB201305813D0 (en) Compositions and methods
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
SG11201604904XA (en) Detergent and rinse-aid compositions and methods
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201308242D0 (en) Compositions and uses thereof
EP3003323A4 (en) POLYSACCARIDE COMPOSITIONS AND CORRESPONDING METHODS
GB201301022D0 (en) Composition and uses thereof
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201319255D0 (en) Therapeutic compositions and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)